Antidote was thrilled to attend the 2024 DIA Convention in San Diego final week! Not solely was it a beautiful alternative to attach with many trade professionals and study from consultants, however it was additionally the celebration of 60 years of DIA. In case you missed it, we’re sharing a few of our key takeaways from the four-day occasion, which centered on charting new horizons in scientific trials.
Busting myths about DEI in scientific analysis
DEI is without doubt one of the mostly mentioned matters in medical analysis, however there are lots of perceived obstacles to implementing really inclusive recruiting practices. In a chat by professionals from PPD, Genentech, H1, and Flourish Analysis, they mentioned most of the challenges and myths surrounding DEI. They shared insights for enhancements that may be made at each degree, specializing in how making inclusive funds choices early choices could make numerous recruitment choices simpler.
Centering the affected person expertise with CAR T-cell remedy
Tom and Emily Whitehead carried out probably the most touching talks of the convention. Emily was identified with acute lymphoblastic leukemia when she was 5 years outdated. After exhausting all remedy choices, her mother and father, Tom and Kari, heard of an experimental CAR T-cell remedy accessible as a Part 1 scientific trial. After enrolling, Emily turned the primary pediatric affected person on this planet to obtain this remedy. Although it was extremely experimental, it was additionally extremely efficient, and Emily has remained cancer-free to today. The dialogue centered across the significance of ongoing analysis and prioritizing the affected person expertise for people collaborating in scientific trials.
The roles AI can play in scientific trials
Whereas AI is without doubt one of the hottest matters of the 12 months, within the case of scientific trials, the thrill round it’s well-deserved. One key speak mentioned how AI is shaping the way forward for scientific trials, together with the methods it may be used to extend return on funding, improve effectivity, and create extra patient-centric participation experiences.